Unlike CAR-T therapy which is mainly concentrated in hematologic malignancies, NK cell therapy has broader application scenarios. It not only shows good prospects in the treatment of solid tumors such as lung cancer, liver cancer and colorectal cancer, but also has potential value in autoimmune diseases, neurological diseases and other fields, making up for the shortcomings of existing treatment methods.

Recently, a delegation from Bangkok Hospital visited Jiahui Health, and the two sides held exchanges focusing on oncology diagnosis, treatment and innovation. The two sides focused on cutting-edge topics in clinical oncology – ranging from surgical operations to advanced and sophisticated therapies such as CAR-T, as well as the application practice of new anti-tumor drugs in China.

The application of CAR-T cell therapy provides new treatment options for patients. Clinical evidence shows that CAR-T cell therapy has achieved remarkable efficacy in hematological malignancies, with some patients even achieving complete remission. All currently approved cellular products have reported these longterm durable responses. Studies show that 83% of lymphoma patients achieve remission after receiving CAR-T cell therapy, of whom 53% achieve complete remission [2].

Malignant tumors are one of the major diseases seriously threatening human health and life, Based on existing evidence-based medical evidence, combined with domestic and international guidelines and consensuses, the Chinese Anti-Cancer Association (CACA) has formulated these Guidelines for the Clinical Application of Malignant Tumor Immunotherapy Technologies, aiming to provide assistance to clinicians engaged in clinical immunotherapy.

At the 2025 American Society of Hematology (ASH) Annual Meeting, Senior journalist Peter Goodwin from Audio Journal of Oncology invited Professor Du Juan from Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine for an on-site interview regarding her team’s research: "FasTCAR-T (GC012F/AZD0120) targeting both BCMA and CD19 as a first-line treatment for newly diagnosed multiple myeloma (NDMM)."

Novel cell therapy shows potential: As an emerging cellular immunotherapy method, CAR-NK cell therapy can still be effective in patients who have failed CAR-T treatment. With mild CRS (cytokine release syndrome) reaction and good safety, it provides a new treatment option for refractory and relapsed patients and is expected to become an important treatment direction for such patients in the future;

Multiple Myeloma (MM) is the second most common hematological malignancy worldwide and the third most common in China. It originates from plasma cells in the bone marrow, which are "immune warriors" that normally synthesize antibodies to fight infection. When these cells become malignant, they proliferate uncontrollably, crowding out healthy cells and destroying bone and kidney functions. Due to its insidious onset and diverse symptoms, the misdiagnosis rate is as high as 50%

A Belgian MS patient, Alex, regained his life after CAR-T therapy in China - from wheelchair-bound to walking and embracing his child again. Huazhong University's Professor Wang Wei team pioneered the breakthrough, proving CAR-T can safely cross the blood-brain barrier to clear pathogenic B cells in CNS. Published in Cell, this marks a milestone in autoimmune disease treatment.

Lu Daopei Hospital's dual-target CAR-T saves critically ill international DLBCL patient! A 60-year-old Egyptian with massive abdominal tumor & TP53 mutations achieved remarkable recovery after CD19/CD22 CAR-T + radiotherapy. From unable to sit to walking out smiling.